Core Viewpoint - The low-price strategy of the medical beauty company New Oxygen has intensified conflicts with upstream suppliers, leading to resistance from multiple vendors and a significant drop in its stock price [2][3]. Group 1: Supplier Conflicts - On December 11, the collagen filler manufacturer Faiman Biotech announced it had stopped supplying products to New Oxygen since October 1, claiming that continued sales would imply products were obtained from non-compliant channels or were counterfeit [2]. - Another manufacturer, Puliyan, listed over 40 New Oxygen clinics as "non-official cooperative medical institutions," while Saint Boma stated that New Oxygen's sales of its product "Aivilan" were through non-compliant channels [2][3]. - In response to supplier pushback, New Oxygen's clinic issued a statement accusing suppliers of maintaining a high-price system that undermines the pricing autonomy of medical institutions [2]. Group 2: Pricing Strategy - New Oxygen's pricing strategy has led to significant price reductions, with its own brand "Miracle Youth 3.0" priced at 999 yuan for the basic version and 2999 yuan for the upgraded version, while similar products from major brands are priced above 10,000 yuan [3][4]. - The company has been able to sell products at prices significantly lower than the original manufacturers by eliminating middlemen and utilizing lower-cost contract manufacturing [4]. - A recent promotion on New Oxygen's platform offered a product originally priced at 1999 yuan for as low as 949 yuan, resulting in over 22,000 units sold by December 15 [4]. Group 3: Market Dynamics - The medical beauty industry is experiencing a competitive landscape where New Oxygen's low-price model is seen as a survival strategy amid fierce competition [5]. - The products sold by New Oxygen are classified as approved Class III medical devices, but concerns remain regarding the quality control and long-term safety of newer domestic brands compared to established international ones [5]. - The ongoing conflict between New Oxygen and its suppliers is expected to have limited deep-seated impacts on the manufacturers, serving primarily to delineate boundaries publicly [5].

Core Viewpoint - The article discusses the recent conflicts between medical beauty company New Oxygen and its upstream suppliers due to New Oxygen's low pricing strategy, which has led to a significant drop in its stock price and supplier resistance [3][6]. Summary by Sections Supplier Conflicts - New Oxygen's low pricing strategy has intensified conflicts with suppliers, leading to several suppliers, including Faiman Bio, ceasing to supply products to New Oxygen since October 1 [3][4]. - Suppliers claim that New Oxygen's pricing disrupts the market's pricing system, resulting in a "supply cut" from multiple manufacturers [5][6]. Pricing Strategy - New Oxygen offers its own brand of "童颜针" (youthful needle) products at significantly lower prices compared to the market, with prices as low as 999 yuan for the basic version and 2999 yuan for the upgraded version [5]. - The article highlights that while major brands price their products above 10,000 yuan, New Oxygen's pricing strategy allows it to sell similar products for much lower prices, attracting a large customer base [5][6]. Business Model - New Oxygen's business model is characterized by using low prices as a customer acquisition strategy, collaborating with upstream manufacturers to eliminate middlemen and reduce costs [6][7]. - The company reportedly utilizes lower-cost OEM production methods, allowing it to maintain high profit margins despite lower retail prices [6][7]. Market Impact - The ongoing conflict between New Oxygen and its suppliers is expected to have limited long-term effects on the overall market, with the public disputes serving to clarify positions among the involved parties [8].

Core Viewpoint - The low-price strategy of the medical beauty company New Oxygen has intensified conflicts with upstream suppliers, leading to resistance from multiple vendors and a significant drop in its stock price [1][3]. Group 1: Pricing Strategy and Market Impact - New Oxygen's model involves attracting customers through low prices by collaborating with upstream manufacturers of "童颜针" (youthful needle) and eliminating intermediaries to significantly reduce product costs and achieve higher profits [1][4]. - The company's pricing for "童颜针" products is substantially lower than the market average, with some products priced at 4999 yuan and 5999 yuan, compared to official prices exceeding 10,000 yuan [3][4]. - New Oxygen's aggressive pricing strategy has disrupted the market's pricing system, prompting suppliers to cut off supplies [4]. Group 2: Supplier Relations and Compliance Issues - Suppliers, including斐缦生物 and 普丽妍, have publicly declared New Oxygen as a non-compliant partner, halting supplies and labeling its sales as potentially involving counterfeit products [1][3]. - Despite supplier claims, New Oxygen continues to sell certain products, asserting that they are traceable through official channels [3]. - The compliance of New Oxygen's products is under scrutiny, as newer domestic brands may lack the long-term safety data compared to established international brands [5]. Group 3: Business Model and Industry Context - New Oxygen's business model is seen as a survival strategy in a competitive medical beauty market, leveraging excess production capacity from smaller brands to offer low-priced products [5]. - The industry comparison to smartphone branding illustrates how lower-priced products can still maintain profitability despite significant price differences from premium brands [4][5]. - The ongoing conflict with suppliers is expected to have limited deep impacts on the overall market, serving primarily to clarify positions among the involved parties [5].